MedTrace Logo

Tolerability of SLIT With LAIS® Mites Allergoid Tablets

NCT02609581 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 192

Last updated 2017-10-25

No results posted yet for this study

Summary

To expand knowledge on the application and tolerability of immunotherapy with LAIS® Mites allergoid tablets as well as knowledge on the alleviation of symptoms during sublingual therapy in special consideration of the chosen titration schedule in everyday practice.

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Sublingual Immunotherapy with tablets (mites)

Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.

Sponsors & Collaborators

  • University Hospital of Cologne

    lead OTHER

Principal Investigators

  • Ralph Mösges, Prof. Dr. · University Hospital Cologne

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-12-01
Primary Completion
2017-02-28
Completion
2017-02-28

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02609581 on ClinicalTrials.gov